NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaMarginal Zone LymphomaWaldenstrom MacroglobulinemiaBurkitt's LymphomaPrimary CNS Lymphoma

Interventions

DRUG

19(T2)28z1xx CAR T cells

2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale